Abstract P2-09-20: Impact of body mass index (BMI) on the safety and efficacy of ribociclib (RIB) in patients (pts) with HR+/HER2- advanced breast cancer (ABC): pooled analysis of the MONALEESA (ML)-2, -3, and -7 trials
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-p2-09-20
Abstract: Background: Studies evaluating the relationship between BMI and outcomes in breast cancer have had conflicting results. While some studies have found obesity to be associated with lower efficacy in early breast cancer, the same relationship… read more here.
Keywords: rib; breast cancer; efficacy; bmi ... See more keywords
Abstract PS8-04: Targeting clinically advanced breast cancer with conjugated and unconjugated HER2 antibodies: Does copy number matter?
Sign Up to like & getrecommendations! Published in 2025 at "Clinical Cancer Research"
DOI: 10.1158/1557-3265.sabcs24-ps8-04
Abstract: Background: HER2-targeted therapy is broadly used in advanced breast cancer (aBC). For HER2+ aBC (HER2 IHC 3+ or 2+/ISH+), 1L standard of care includes unconjugated HER2 antibodies trastuzumab and pertuzumab (HP) in combination with chemotherapy.… read more here.
Keywords: cancer; breast; her2 ratio; her2 ... See more keywords
A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.tps1112
Abstract: TPS1112Background: CDK4/6i, including palbociclib and ribociclib (R), have demonstrated remarkable benefit in progression free survival (PFS) in patients (pts) with HR+, HER2- MBC with anti-estrogen therapy. Switching between anti-estrogen therapies at disease progression is standard… read more here.
Keywords: trial; fulvestrant; her2 mbc; inhibition ... See more keywords
Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2- metastatic breast cancer: A machine learning approach.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.1074
Abstract: 1074 Background: CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) are the current standard of care for pts with newly diagnosed HR+/HER2- metastatic breast cancer (MBC). Although multiple pivotal trials showed a robust benefit… read more here.
Keywords: her2 metastatic; risk; response; pts her2 ... See more keywords
Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.3103
Abstract: 3103 Background: Previous preclinical study has shown the antitumor activity of E7090, a novel selective FGFR1–3 inhibitor (i), with endocrine therapy (ET) for ER+, HER2− BC with FGFR signaling dependency after CDK4/6i exposure. In Study… read more here.
Keywords: cohort; her2 recurrent; recurrent metastatic; pts her2 ... See more keywords
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.4565
Abstract: 4565 Background: In DP-02, T-DXd showed robust responses and clinically meaningful survival outcomes in 267 pretreated pts with HER2-expressing solid tumors; the objective response rate (ORR) by investigator (INV) was 37.1% (95% CI 31.3, 43.2).… read more here.
Keywords: expressing solid; safety; solid tumors; bladder cohort ... See more keywords
Results from the phase 1b/2 SGNTUC-024 study: Assessment of tucatinib, trastuzumab, and FOLFOX for HER2+ GI cancers.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.3_suppl.100
Abstract: 100 Background: HER2 is overexpressed in various GI tumors. Tucatinib (TUC), which is approved in combination with trastuzumab (Tras) in the US for previously treated RAS WT HER2+ metastatic colorectal cancer (mCRC), is a tyrosine… read more here.
Keywords: cohort; treatment; study; pts her2 ... See more keywords
Phase 1b/2, open-label dose-escalation and -expansion study evaluating trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with HER2+ and HER2-low gastric cancer (GC): DESTINY-Gastric03 (DG-03).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.3_suppl.tps424
Abstract: TPS424 Background: T-DXd is approved for treatment of advanced/metastatic HER2+ GC after a trastuzumab-based regimen. The efficacy of T-DXd in advanced HER2+ (IHC 3+ or IHC 2+/ISH+) GC has been shown (confirmed objective response rate… read more here.
Keywords: ihc; dxd; her2 low; part ... See more keywords
Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.1079
Abstract: 1079 Background: Tumors develop resistance following 1L endocrine therapy (ET) + CDK4/6i in ER+/HER2- mBC. Elacestrant (Ela) significantly improved PFS vs standard-of-care (SOC) ET ( ESR1 -mut tumors HR 0.55; 95% CI 0.39-0.77; P=0.0005; all… read more here.
Keywords: ela; nausea; ela 345; pts her2 ... See more keywords
Disitamab vedotin (DV) plus toripalimab (Tor) and chemotherapy (C)/trastuzumab (Tra) as first-line (1L) treatment of patients (pts) with HER2-expressing locally advanced or metastatic (la/m) gastric cancer.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.17_suppl.lba4012
Abstract: LBA4012 Background: DV+T showed encouraging efficacy with manageable safety for pts with HER2-expressing gastric or gastroesophageal junction (G/GEJ) cancer in the second- and later-line setting in a phase 1 trial (Wang et al, eClinicalMedicine, 2024).… read more here.
Keywords: tor; cancer; 100 100; stage ... See more keywords